Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Detaylı Bibliyografya
Asıl Yazarlar:	Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	European Respiratory Society 2018

Benzer Materyaller

Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Investigating blood eosinophil count thresholds in patients with COPD
Yazar:: Russell, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Case series of long-term macrolide therapy effect on eosinophil count in COPD
Yazar:: Asciak, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Blood eosinophil count and exacerbation risk in patients with COPD.
Yazar:: Kerkhof, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Characterising non-eosinophilic COPD
Yazar:: Hambleton, K, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Eosinophils in COPD: just another biomarker?
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Yazar:: Bafadhel M, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis
Yazar:: Antonella Casiraghi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Variability of blood eosinophil count and prognosis of COPD exacerbations
Yazar:: Sandra Martínez-Gestoso, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Blood eosinophil count as a prognostic biomarker in COPD
Yazar:: Oh YM, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Eosinophil migration is enhanced towards IL-5 and eotaxin in COPD
Yazar:: Lababidi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
Yazar:: Djamin, R, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis
Yazar:: Antonio Spennacchio, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement
Yazar:: Manzetti GM, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD
Yazar:: Tomoki Maetani, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
Yazar:: Shigeo Muro, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Can NPT be used to distinguish eosinophilic inflammatory phenotypes in COPD?
Yazar:: Hambleton, K, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Prediction value of neutrophil and eosinophil count at risk of COPD exacerbation
Yazar:: Tzu-Tao Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Current smoking reduces small airway eosinophil counts in COPD
Yazar:: Augusta Beech, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
Yazar:: Shigeo Muro, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects
Yazar:: Hambleton, K, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Association between blood eosinophil count and risk of exacerbations in patients with COPD
Yazar:: Kerkhof, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Blood eosinophil count correlates with alveolar damage in emphysema-predominant COPD
Yazar:: Saya Nakamura, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Identification of COPD Inflammatory Endotypes Using Repeated Sputum Eosinophil Counts
Yazar:: Augusta Beech, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort
Yazar:: Greulich T, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

Blood eosinophil count predicts treatment failure and hospital readmission for COPD
Yazar:: Marjan Kerkhof, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Budesonide/formoterol combination in COPD: a US perspective
Yazar:: Amir Sharafkhaneh, ve diğerleri
Baskı/Yayın Bilgisi: (2010-10-01)

Late breaking abstract - Resistomics of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of antimicrobial-resistance-encoding genes
Yazar:: Ramsheh, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis
Yazar:: Caroline Michèle Andrist, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Clinical implications of blood eosinophil count in patients with non-asthma–COPD overlap syndrome COPD
Yazar:: Song JH, ve diğerleri
Baskı/Yayın Bilgisi: (2017-08-01)

Blood Eosinophils and outcomes in severe hospitalized exacerbations of COPD
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
Yazar:: Russell, R, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma
Yazar:: George, L, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization
Yazar:: Bélanger M, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
Yazar:: Belchamber KBR, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2014)